Arrhythmogenic Right Ventricular Dysplasia Market | 2031
Arrhythmogenic Right Ventricular Dysplasia Market | 2031
Segments - Arrhythmogenic Right Ventricular Dysplasia Market by Treatment (Surgical and Non-surgical), End-user (Ambulatory Surgical Centers, Hospitals, Ambulatory care centers, Clinics, Diagnostics Imaging Centers, and Others), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-5832
| 4.9 Rating
| 65 Reviews
| 175 Pages
| Format :
Report Description
Arrhythmogenic Right Ventricular Dysplasia Market Outlook 2031
The global arrhythmogenic right ventricular dysplasia market size was valued at USD 0.98 billion in 2023 and is likely to reach USD 1.28 billion by 2031, expanding at a CAGR of 4.7% during 2023 – 2031. The growth of the market is attributed to the increasing demand for diagnostic and treatment solutions to treat rare cardiovascular diseases.
Rising number of people diagnosed with arrhythmogenic right ventricular dysplasia (ARVD) is driving the need for improved diagnostic tools, treatment options, and ongoing care, which in turn, is boosting the market.
ARVD is a rare heart disorder that affects the right ventricle, one of the heart's chambers. Additionally, this rare disease increases the risk of life-threatening heart diseases affecting individuals of all age types.
-
According to the report published by the National Library of Medicine on July 24, 2023, stating that the occurrence of ARVC/D in the general population is between 1 in 2500 to 1 in 5000. Additionally, these disorders account for 5% to 10% of sudden deaths in people under the age of 65.
In ARVD, the muscle tissue in the right ventricle becomes replaced by fat and fibrous tissue. This disrupts the heart's electrical signals and causes abnormal heart rhythms called arrhythmias. Additionally, these irregular heart rhythms lead to symptoms, such as palpitations, dizziness, fainting, and a high risk of sudden cardiac arrest.
The research reports find that the COVID-19 pandemic is hampering the market. The pandemic postponed or cancellated non-urgent medical procedures, including diagnostic tests. Many people with ARVD rely on tests, such as electrocardiograms (ECGs), echocardiograms, and cardiac magnetic resonance imaging (MRI) for diagnosis and ongoing monitoring. Delays in these tests hindered timely detection and management of the condition leading to severe health consequences.
Artificial Intelligence (AI) Impact on Arrhythmogenic Right Ventricular Dysplasia Market
Emergence of artificial intelligence is expected to propel the market. AI is being employed to enhance the accuracy and efficiency of diagnosing and managing ARVD. AI algorithms analyze medical imaging data and aid in early detection and risk assessment. Additionally, AI-driven predictive models help in identifying individuals at high risk of developing ARVD, which allows for proactive interventions.
Arrhythmogenic Right Ventricular Dysplasia Market Dynamics
Major Drivers
Growing occurrence of congenital heart diseases is expected to drive the market. The high number of people born with heart conditions raises the overall awareness and concern for heart-related disorders, including ARVD. This heightened focus prompts research and medical advancements in the field. Moreover, increasing number of children born with CHDs is further propelling the market.
-
According to a report published by the Centers for Disease Control and Prevention on September 19, 2023, approximately 1% or 40,000 births in the US are affected by CHDs annually.
Existing Restraints
Limited treatment options are expected to hinder market growth. Treatment options for ARVD are still relatively limited compared to common heart conditions. This constraint stems from the rarity of ARVD, which makes it less attractive for pharmaceutical companies to invest in the development of specific drugs or therapies. Furthermore, the high complexity of diagnosis and the cost of treating ARVDs further hampers the market.
Emerging Opportunities
Ongoing R&D activities are expected to create immense opportunities for the players competing in the market. Pharmaceutical companies are focusing on utilizing the latest medical technologies, including modern imaging equipment, and genetics.
These advancements enhance the precision and speed of ARVD diagnosis. Moreover, integration of telemedicine and remote monitoring technologies is improving the way ARVD patients receive care, which boosts the market.
Scope of the Arrhythmogenic Right Ventricular Dysplasia Market Report
The report on the market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Arrhythmogenic Right Ventricular Dysplasia Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Treatment (Surgical and Non-surgical) and End-user (Ambulatory Surgical Centers, Hospitals, Ambulatory care centers, Clinics, Diagnostics Imaging Centers, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Aetna Inc; Ambry Genetics; Asper Biogene LLC; Blueprint Genetics Oy; CENTOGENE N.V.; Cohesion Phenomics; GeneDx, LLC; Illumina Inc; Invitae Corporation; Medanta The Medicity(Global Health Limited); and Tenaya Therapeutics |
Arrhythmogenic Right Ventricular Dysplasia Market Segment Insights
Treatment Analysis
Based on treatment, the arrhythmogenic right ventricular dysplasia market is divided into surgical and non-surgical. The surgical segment is anticipated to register robust growth during the forecast period, as surgical interventions are important in managing this condition effectively.
ARVD often involves structural abnormalities in the heart and surgery is often required to address these issues. Additionally, the surgical procedure for ARVD is the implantation of cardioverter-defibrillators (ICDs) to prevent life-threatening invents. These factors are fueling the market.
End-user Analysis
In terms of end-user, the market is fragmented into ambulatory surgical centers, hospitals, ambulatory care centers, clinics, diagnostics imaging centers, and others. The hospital segment is projected to register a considerable CAGR during the forecast period due to the presence of specialized cardiology departments with experienced cardiologists and electrophysiologists.
This expertise is important for accurate diagnosis and effective management of cardiac arrhythmias and conditions, including ARVD. Moreover, the hospitals possess modern medical equipment to cater vast number of ARVD patient and contributes to fueling the segment.
Regional Outlook
In terms of region, the global arrhythmogenic right ventricular dysplasia market is segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market due to the presence of highly advanced and well-established healthcare infrastructure.
This infrastructure supports the diagnosis and treatment of ARVD with modern equipment and specialized expertise. Moreover, the growing number of deaths associated with cardiovascular disease, including ARVD boosts the market in this region.
-
According to the report published by the Centers for Diseases and Prevention on May 15, 2023, stating that cardiovascular disease was a leading reason of death in the US, claiming the lives of 696,000 individuals in 2021. Shockingly, one person in the US dies every 33 seconds due to heart diseases.
The market in Asia Pacific is anticipated to expand at a rapid pace in the coming years, as many countries in this region are investing in their healthcare infrastructure. This includes the development of modern hospitals, cardiac care centers, and diagnostic facilities for conditions, including ARVD. Furthermore, growing elderly population fuels the demand for ARVD diagnosis and management in this region.
-
As per the report published by the United States Census Bureau on June 21, 2022, Eastern Asia's population of people aged 65 and above is projected to be 33.7% by 2060.
Segments
The global arrhythmogenic right ventricular dysplasia market has been segmented on the basis of
Treatment
- Surgical
- Non-surgical
End-user
- Ambulatory Surgical Centers
- Hospitals
- Ambulatory care centers
- Clinics
- Diagnostics Imaging Centers
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Aetna Inc
- Ambry Genetics
- Asper Biogene LLC
- Blueprint Genetics Oy
- CENTOGENE N.V.
- Cohesion Phenomics
- GeneDx, LLC
- Illumina Inc
- Invitae Corporation
- Medanta The Medicity(Global Health Limited)
- Tenaya Therapeutics
Competitive Landscape
Key players competing in the global arrhythmogenic right ventricular dysplasia market are Aetna Inc; Ambry Genetics; Asper Biogene LLC; Blueprint Genetics Oy; CENTOGENE N.V.; Cohesion Phenomics; GeneDx, LLC; Illumina Inc; Invitae Corporation; Medanta The Medicity(Global Health Limited); and Tenaya Therapeutics.
These companies are boosting their market share by adopting various strategies such as partnerships, mergers, acquisitions, and implementing advanced AI technologies in the manufacturing process.
-
On October 26, 2023, Tenaya Therapeutics, a multinational biotechnology company, announced that the FDA had cleared its Investigational New Drug (IND) application to begin clinical testing of TN-401. TN-401 is an investigational gene therapy product that is specifically designed to treat ARVC, which is primarily caused by mutations in the plakophilin-2 (PKP2) gene.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Arrhythmogenic Right Ventricular Dysplasia Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Arrhythmogenic Right Ventricular Dysplasia Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Arrhythmogenic Right Ventricular Dysplasia Market - Supply Chain
4.5. Global Arrhythmogenic Right Ventricular Dysplasia Market Forecast
4.5.1. Arrhythmogenic Right Ventricular Dysplasia Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Arrhythmogenic Right Ventricular Dysplasia Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Arrhythmogenic Right Ventricular Dysplasia Market Absolute $ Opportunity
5. Global Arrhythmogenic Right Ventricular Dysplasia Market Analysis and Forecast by End Users
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by End Users
5.2.2. Y-o-Y Growth Projections by End Users
5.3. Arrhythmogenic Right Ventricular Dysplasia Market Size and Volume Forecast by End Users
5.3.1. Ambulatory Surgical Centers
5.3.2. Hospitals
5.3.3. Ambulatory care centers
5.3.4. Clinics
5.3.5. Diagnostics Imaging Centers
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by End Users
5.5. Market Attractiveness/Growth Potential Analysis by End Users
6. Global Arrhythmogenic Right Ventricular Dysplasia Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Arrhythmogenic Right Ventricular Dysplasia Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Arrhythmogenic Right Ventricular Dysplasia Demand Share Forecast, 2019-2026
7. North America Arrhythmogenic Right Ventricular Dysplasia Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Arrhythmogenic Right Ventricular Dysplasia Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Arrhythmogenic Right Ventricular Dysplasia Market Size and Volume Forecast by End Users
7.4.1. Ambulatory Surgical Centers
7.4.2. Hospitals
7.4.3. Ambulatory care centers
7.4.4. Clinics
7.4.5. Diagnostics Imaging Centers
7.4.6. Others
7.5. Basis Point Share (BPS) Analysis by End Users
7.6. Y-o-Y Growth Projections by End Users
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Arrhythmogenic Right Ventricular Dysplasia Demand Share Forecast, 2019-2026
8. Latin America Arrhythmogenic Right Ventricular Dysplasia Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Arrhythmogenic Right Ventricular Dysplasia Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Arrhythmogenic Right Ventricular Dysplasia Market Size and Volume Forecast by End Users
8.4.1. Ambulatory Surgical Centers
8.4.2. Hospitals
8.4.3. Ambulatory care centers
8.4.4. Clinics
8.4.5. Diagnostics Imaging Centers
8.4.6. Others
8.5. Basis Point Share (BPS) Analysis by End Users
8.6. Y-o-Y Growth Projections by End Users
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Arrhythmogenic Right Ventricular Dysplasia Demand Share Forecast, 2019-2026
9. Europe Arrhythmogenic Right Ventricular Dysplasia Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Arrhythmogenic Right Ventricular Dysplasia Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Arrhythmogenic Right Ventricular Dysplasia Market Size and Volume Forecast by End Users
9.4.1. Ambulatory Surgical Centers
9.4.2. Hospitals
9.4.3. Ambulatory care centers
9.4.4. Clinics
9.4.5. Diagnostics Imaging Centers
9.4.6. Others
9.5. Basis Point Share (BPS) Analysis by End Users
9.6. Y-o-Y Growth Projections by End Users
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Arrhythmogenic Right Ventricular Dysplasia Demand Share Forecast, 2019-2026
10. Asia Pacific Arrhythmogenic Right Ventricular Dysplasia Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Arrhythmogenic Right Ventricular Dysplasia Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Arrhythmogenic Right Ventricular Dysplasia Market Size and Volume Forecast by End Users
10.4.1. Ambulatory Surgical Centers
10.4.2. Hospitals
10.4.3. Ambulatory care centers
10.4.4. Clinics
10.4.5. Diagnostics Imaging Centers
10.4.6. Others
10.5. Basis Point Share (BPS) Analysis by End Users
10.6. Y-o-Y Growth Projections by End Users
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Arrhythmogenic Right Ventricular Dysplasia Demand Share Forecast, 2019-2026
11. Middle East & Africa Arrhythmogenic Right Ventricular Dysplasia Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Arrhythmogenic Right Ventricular Dysplasia Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Arrhythmogenic Right Ventricular Dysplasia Market Size and Volume Forecast by End Users
11.4.1. Ambulatory Surgical Centers
11.4.2. Hospitals
11.4.3. Ambulatory care centers
11.4.4. Clinics
11.4.5. Diagnostics Imaging Centers
11.4.6. Others
11.5. Basis Point Share (BPS) Analysis by End Users
11.6. Y-o-Y Growth Projections by End Users
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Arrhythmogenic Right Ventricular Dysplasia Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Arrhythmogenic Right Ventricular Dysplasia Market: Market Share Analysis
12.2. Arrhythmogenic Right Ventricular Dysplasia Distributors and Customers
12.3. Arrhythmogenic Right Ventricular Dysplasia Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Aetna Inc
12.4.2. Ambry Genetics
12.4.3. Asper Biogene LLC
12.4.4. Blueprint Genetics Oy
12.4.5. CENTOGENE N.V.
12.4.6. Cohesion Phenomics
12.4.7. GeneDx, LLC
12.4.8. Illumina Inc
12.4.9. Invitae Corporation
12.4.10. Medanta The Medicity(Global Health Limited)
12.4.11. Tenaya Therapeutics
Methodology
Related Reports
Some other reports from this category!
Our Clients
